Summit Corporation
London
United Kingdom
34 articles about Summit Corporation
-
Summit Corporation Awarded BARDA Contract Worth Up To $62 Million To Support Development Of Ridinilazole For CDI
9/11/2017
-
Summit Corporation Files Registration Statement For Proposed U.S. Public Offering And Applies For NASDAQ Listing
2/2/2015
-
Summit Corporation Appoints Erik Ostrowski As Chief Financial Officer
6/23/2014
-
Summit Corporation Announces FDA Clearance Of IND Application For Phase 2 Study Of SMT19969 To Treat C. Difficile Infection
3/18/2014
-
Summit Corporation Announces First Patient Dosed In A Phase 1b Clinical Trial Of Smt C1100 For Treatment Of Duchenne Muscular Dystrophy
12/9/2013
-
Summit Corporation And The University of Oxford Enter Strategic Alliance To Develop Treatments For Duchenne Muscular Dystrophy
11/25/2013
-
Summit Corporation Awarded £2.4 Million From the UK Biomedical Catalyst Fund to Support the Development of DMD Therapy
7/31/2013
-
Summit Corporation Achieves Clinical Milestone Triggering £740,000 Payment From Wellcome Trust to Fund Novel C. Difficile Antibiotic
6/17/2013
-
Summit Corporation Outlines Clinical Development Plans for Utrophin Modulator Program for Duchenne Muscular Dystrophy
3/21/2013
-
Summit Corporation Forms Advisory Board to Support Development of Duchenne Muscular Dystrophy Program
2/13/2013
-
Summit Corporation and Children's National Medical Center Enter Utrophin Biomarker Collaboration for Duchenne Muscular Dystrophy
2/6/2013
-
Summit Corporation Release: Repeat Dosing of SMT C1100 for Treatment of Duchenne Muscular Dystrophy Meets Endpoints in Phase 1 Clinical Trial
11/7/2012
-
Summit Corporation Awarded Up to $3.6 Million From the Wellcome Trust to Support Clinical Development of Selective C. Difficile Antibiotic
10/22/2012
-
Summit Corporation Announces Positive Phase 1 Trial Results for SMT C1100 for Treatment of Duchenne Muscular Dystrophy
10/10/2012
-
Summit Corporation Receives Regulatory Approval to Commence Phase I Clinical Trial of Selective Antibiotic for the Treatment of C. Difficile Infections
9/25/2012
-
Summit Corporation Inks Breakthrough Seglin Deal With Bristol-Myers Squibb Company
9/11/2012
-
Summit Corporation Interim Results for the Six Months Ended 31 July 2012
9/6/2012
-
Summit Corporation Notified of Grant Award From UK Technology Strategy Board
8/2/2012
-
Summit Corporation's Annual General Meeting Statement
7/18/2012
-
Summit Corporation Presents New Data on OGA Inhibition at Alzheimer’s Association International Conference
7/17/2012